Gabriella D’Andrea

4.4k total citations · 1 hit paper
60 papers, 2.7k citations indexed

About

Gabriella D’Andrea is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Gabriella D’Andrea has authored 60 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Oncology, 17 papers in Cancer Research and 16 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Gabriella D’Andrea's work include Cancer Treatment and Pharmacology (35 papers), HER2/EGFR in Cancer Research (30 papers) and Breast Cancer Treatment Studies (14 papers). Gabriella D’Andrea is often cited by papers focused on Cancer Treatment and Pharmacology (35 papers), HER2/EGFR in Cancer Research (30 papers) and Breast Cancer Treatment Studies (14 papers). Gabriella D’Andrea collaborates with scholars based in United States, Italy and Canada. Gabriella D’Andrea's co-authors include Andrew D. Seidman, Larry Norton, Clifford A. Hudis, Maura N. Dickler, Shanu Modi, Monica Fornier, Katherine S. Panageas, Chau T. Dang, Mark M. Moasser and Monique M.E.M. Bos and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Radiology.

In The Last Decade

Gabriella D’Andrea

58 papers receiving 2.7k citations

Hit Papers

Phase I Studies of Anti–Epidermal Growth Factor Receptor ... 2000 2026 2008 2017 2000 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase I Studies of Anti–Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With Cisplatin
    2000 596 citations José Baselga, David G. Pfister et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gabriella D’Andrea United States 24 1.5k 848 785 383 317 60 2.7k
Aaron C. Tan Singapore 21 1.1k 0.7× 960 1.1× 1.4k 1.8× 783 2.0× 278 0.9× 73 3.4k
Uma Raju United States 32 1.0k 0.7× 597 0.7× 1.2k 1.5× 484 1.3× 292 0.9× 102 2.7k
Pierre‐Marie Martin France 34 796 0.5× 562 0.7× 1.3k 1.6× 747 2.0× 152 0.5× 99 3.4k
Xavier Durando France 31 1.0k 0.7× 480 0.6× 886 1.1× 774 2.0× 141 0.4× 140 2.9k
Liang-Shun Wang Taiwan 30 641 0.4× 638 0.8× 951 1.2× 368 1.0× 83 0.3× 61 2.3k
Dimitrios T. Trafalis Greece 20 792 0.5× 245 0.3× 957 1.2× 303 0.8× 95 0.3× 113 2.2k
Paul Delmar Switzerland 23 778 0.5× 588 0.7× 786 1.0× 307 0.8× 139 0.4× 87 2.4k
Wassim Abou‐Kheir Lebanon 33 740 0.5× 545 0.6× 1.4k 1.8× 800 2.1× 71 0.2× 113 3.2k
Banu Arun United States 23 1.8k 1.2× 466 0.5× 1.5k 1.9× 897 2.3× 113 0.4× 58 3.3k
Sacha J. Howell United Kingdom 35 2.1k 1.4× 703 0.8× 1.7k 2.1× 1.0k 2.6× 149 0.5× 146 4.4k

Countries citing papers authored by Gabriella D’Andrea

Since Specialization
Citations

This map shows the geographic impact of Gabriella D’Andrea's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gabriella D’Andrea with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gabriella D’Andrea more than expected).

Fields of papers citing papers by Gabriella D’Andrea

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gabriella D’Andrea. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gabriella D’Andrea. The network helps show where Gabriella D’Andrea may publish in the future.

Co-authorship network of co-authors of Gabriella D’Andrea

This figure shows the co-authorship network connecting the top 25 collaborators of Gabriella D’Andrea. A scholar is included among the top collaborators of Gabriella D’Andrea based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gabriella D’Andrea. Gabriella D’Andrea is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gucalp, Ayca, Mrinal M. Gounder, Sujata Patil, et al.. (2020). Phase II trial of bicalutamide in combination with palbociclib for the treatment of androgen receptor (+) metastatic breast cancer.. Journal of Clinical Oncology. 38(15_suppl). 1017–1017. 26 indexed citations
2.
Weiner, Ashley & Gabriella D’Andrea. (2018). Hidden estrogen production from ovarian remnants leading to progression of disease in metastatic breast cancer. The Breast Journal. 24(4). 642–643. 2 indexed citations
3.
Morris, Patrick G., Karen A. Cadoo, Sujata Patil, et al.. (2018). Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer. Clinical Breast Cancer. 18(5). 387–394. 39 indexed citations
4.
Jhaveri, Komal, Rui Wang, Eleonora Teplinsky, et al.. (2017). A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer. Breast Cancer Research. 19(1). 89–89. 46 indexed citations
5.
Iyengar, Neil M., Monica Fornier, Steven Sugarman, et al.. (2015). A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer. Clinical Breast Cancer. 16(2). 87–94. 2 indexed citations
6.
Dang, Chau T., Neil M. Iyengar, Gabriella D’Andrea, et al.. (2014). Phase II Study of Paclitaxel Given Once per Week Along With Trastuzumab and Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer. Journal of Clinical Oncology. 33(5). 442–447. 55 indexed citations
7.
Shah, Payal D., Shanu Modi, Mary Ellen Moynahan, et al.. (2014). Phase I trial of daily PI3Kα inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC).. Journal of Clinical Oncology. 32(15_suppl). 2605–2605. 9 indexed citations
8.
Ulaner, Gary A., Gabriella D’Andrea, & Hiram S. Cody. (2013). Breast Implant Foreign Body Reaction Mimicking Breast Cancer Recurrence on FDG PET/CT. Clinical Nuclear Medicine. 38(6). 480–481. 13 indexed citations
9.
D’Andrea, Gabriella, Shari Goldfarb, Maria Theodoulou, et al.. (2013). Abstract P2-16-07: Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer with cardiac biomarker data. Cancer Research. 73(24_Supplement). P2–16. 2 indexed citations
10.
Modi, Shanu, Alison Stopeck, Hannah Linden, et al.. (2011). HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab. Clinical Cancer Research. 17(15). 5132–5139. 328 indexed citations
11.
Gucalp, Ayca, SM Tolaney, SJ Isakoff, et al.. (2011). TBCRC 011: Targeting the androgen receptor (AR) for the treatment of AR+/ER-/PR- metastatic breast cancer (MBC).. Journal of Clinical Oncology. 29(15_suppl). TPS122–TPS122. 4 indexed citations
12.
Abbruzzi, A., Gabriella D’Andrea, Teresa Gilewski, et al.. (2010). Abstract P6-12-09: A Phase I-II Trial of Dasatinib (D) in Combination with Weekly (w) Paclitaxel (P) for Patients (Pts) with Metastatic Breast Carcinoma (MBC). Cancer Research. 70(24_Supplement). P6–12. 3 indexed citations
13.
Deng, Gary, Hong Lin, Andrew D. Seidman, et al.. (2009). A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects. Journal of Cancer Research and Clinical Oncology. 135(9). 1215–1221. 145 indexed citations
14.
Sugarman, Steven, Carolyn Wasserheit, Tiffany A. Troso-Sandoval, et al.. (2008). A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma. Breast Cancer Research and Treatment. 115(3). 609–612. 9 indexed citations
15.
Hurria, Arti, Carol L. Rosen, Clifford A. Hudis, et al.. (2006). Cognitive Function of Older Patients Receiving Adjuvant Chemotherapy for Breast Cancer: A Pilot Prospective Longitudinal Study. Journal of the American Geriatrics Society. 54(6). 925–931. 199 indexed citations
16.
Modi, Shanu, Gabriella D’Andrea, Larry Norton, et al.. (2006). A Phase I Study of Cetuximab/Paclitaxel in Patients with Advanced-Stage Breast Cancer. Clinical Breast Cancer. 7(3). 270–277. 74 indexed citations
17.
D’Andrea, Gabriella. (2005). Use of Antioxidants During Chemotherapy and Radiotherapy Should Be Avoided. CA A Cancer Journal for Clinicians. 55(5). 319–321. 168 indexed citations
18.
Dang, Chau T., Andrew J. Dannenberg, Kotha Subbaramaiah, et al.. (2004). Phase II Study of Celecoxib and Trastuzumab in Metastatic Breast Cancer Patients Who Have Progressed after Prior Trastuzumab-Based Treatments. Clinical Cancer Research. 10(12). 4062–4067. 52 indexed citations
19.
Seidman, Andrew D., Maria Theodoulou, Mary Ellen Moynahan, et al.. (2001). Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.. PubMed. 7(12). 3934–41. 25 indexed citations
20.
Baselga, José, David G. Pfister, Michael R. Cooper, et al.. (2000). Phase I Studies of Anti–Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With Cisplatin. Journal of Clinical Oncology. 18(4). 904–904. 596 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aaron C. Tan Breakdown of academic impact, for papers by Uma Raju Breakdown of academic impact, for papers by Pierre‐Marie Martin Breakdown of academic impact, for papers by Xavier Durando Breakdown of academic impact, for papers by Liang-Shun Wang Breakdown of academic impact, for papers by Dimitrios T. Trafalis Breakdown of academic impact, for papers by Paul Delmar Breakdown of academic impact, for papers by Wassim Abou‐Kheir Breakdown of academic impact, for papers by Banu Arun Breakdown of academic impact, for papers by Sacha J. Howell
Rankless by CCL
2026